Direct-targeting monoclonal antibodies (mAbs) approved for usage in oncology mainly belong to the immunoglobulin (Ig) G class currently. In fact, non-IgG therapeutic antibodies come of age with major progress in different kinds of human diseases, such as cancers and chronic inflammation. IgG mAb is no longer the only player in the therapeutic fields owing to antibody engineering technique, which is further driving the development of novel antibody formats. Besides, genetically modified cell-based therapies that harness the power of the immune system, together with non-IgG therapeutic antibodies, have improved cures in intractable human diseases. Learn more: IgE antibody engineering
1 Agree
Created
SEO JESUS at May 31, 2025 at 8:23am PDT
Ever heard of slimjaro? Let’s unpack what it does, how it works, and whether it’s the right solution for you.
SEO JESUS at May 31, 2025 at 1:09pm PDT
Here’s what you need to know about prime biome — from its real-world benefits to whether it can actually deliver on the promises.
SEO JESUS at May 31, 2025 at 2:01pm PDT
Ever heard of prime biome? Let’s unpack what it does, how it works, and whether it’s the right solution for you.
Robin jack at June 01, 2025 at 3:58am PDT
This internet site is my breathing in, really good layout and perfect content . tigoals live
SEO JESUS at June 01, 2025 at 1:29pm PDT
Here’s what you need to know about prostavive — from its real-world benefits to whether it can actually deliver on the promises.
SEO JESUS at June 01, 2025 at 2:21pm PDT
Ever heard of prostavive? Let’s unpack what it does, how it works, and whether it’s the right solution for you.